Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

HPV-Vaccinated Patients Require Less Frequent Cervical Cancer Screening

November 17th 2016

Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended, according to new findings released from the Harvard T.H. Chan School of Public Health.

Dr. Michael Birrer on Immunotherapy Potential in Cervical Cancer

November 16th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses recent advancements in cervical cancer.

More Than Half of Cervical Cancer Patients Not Receiving Recommended Treatment

November 8th 2016

Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.

Pembrolizumab Shows Promising Antitumor Activity in Cervical Cancer

September 30th 2016

Pembrolizumab (Keytruda) was well tolerated and demonstrated promising antitumor activity in patients with PD-L1–positive advanced cervical squamous cell cancer.

Study Shows Cervical Cancer Screening Reduces Mortality

September 29th 2016

Regular screening for cervical cancer was found to be associated with an overall mortality prevention rate of 83%.

Fewer GI, GU Toxicities With Postoperative Pelvic IMRT in Gynecologic Malignancies

September 29th 2016

Patients with endometrial and cervical cancer reported significantly less acute gastrointestinal toxicity when treated with pelvic intensity-modulated radiation therapy as opposed to standard pelvic radiation therapy.

Metformin May Improve Outcomes in Endometrial Cancer

September 23rd 2016

Combining the diabetes drug metformin with everolimus and letrozole resulted in a clinical benefit rate of 60% in women with advanced or recurrent endometrioid endometrial cancer.

Vaginal Brachytherapy Linked to Improved Survival in Endometrial Cancer

September 7th 2016

Vaginal brachytherapy has been linked to improved survival in women with stage I endometrioid adenocarcinoma of the uterus.

Risk Factors Identified for Detrimental Delays in Endometrial Cancer Surgery

September 2nd 2016

Emily M. Ko, MD, discusses the implications of two clinical trial findings for patients with endometrial cancer, and how several risk factors may lead to a surgical treatment delay.

Dr. Ko on Surgery as an Effective Option for Patients With Endometrial Cancer

August 23rd 2016

Emily Ko, MD, assistant professor of Obstetrics and Gynecology, University of Pennsylvania Health System, discusses why surgery is an effective option for patients with endometrial cancer.

Rio Grande Urology Expands With Gynecologic Oncology Collaboration

August 14th 2016

As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it.

FDA Approves First HPV Test for Use With SurePath Preservative Fluid

July 8th 2016

The FDA has approved the cobas HPV Test for use with SurePath Preservative Fluid for the detection of human papilloma virus (HPV) in cervical cells.

NCCN Introduces New Vulvar Cancer Guideline

April 4th 2016

A new NCCN guideline for the management of vulvar cancer outlines the use of resection, radiation therapy, and chemotherapy based on disease site and stage, recognizing that only 2 randomized treatment trials have been completed.

Trabectedin Significantly Slows Progression in Uterine Leiomyosarcoma

March 20th 2016

Treatment with trabectedin significantly improved progression-free survival compared with dacarbazine in women with advanced uterine leiomyosarcoma, according to a subgroup analysis of the phase III SAR-3007 trial.

Expert Sees Major Genomic Knowledge Gaps in Cervical Cancer

January 19th 2016

Today, in his laboratory at Columbia University, Murty Vundavalli, PhD continues working to understand the genetic and epigenetic aspects of cervical cancer in an attempt to elucidate prognostic markers of response to treatment.

Genome Sequencing Hints at New Targets for Cervical Cancer

January 14th 2016

With technological advancements in genome sequencing, researchers are now gaining a more detailed picture of the genetic drivers of cervical cancer and the important role that the human papillomavirus, responsible for the vast majority of cervical cancer cases, plays in molding the genetic profile of this disease.

BRCA+ Patients May Have Higher Risk of Serous Uterine Cancers After RRSO

October 15th 2015

Dr. Noah Kauff discusses how hysterectomy, in addition to standard risk-reducing salpingo-oophorectomy (RRSO) measures, should be considered in BRCA+women to reduce the risk of serous uterine cancers.

Fosaprepitant Improves Emesis Control in Women Receiving Chemoradiotherapy for Cervical Cancer

September 28th 2015

Adding fosaprepitant (Emend) to an antiemetic regimen significantly improved emesis control versus standard care in women receiving radiotherapy and cisplatin for cervical cancer.

Novel Immunotherapy Shows Promise in Metastatic Cervical Cancer

September 17th 2015

Tom Herzog, MD, discusses the vaccine ADXS11-001 (axalimogene filolisbac) in patients with persistent or recurrent metastatic cervical cancer.

Dr. Kauff on Challenges in Treating Uterine Cancer

August 19th 2015

Noah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the main challenges in treating uterine cancer.